فارما جو – عمان قامت شركة سنا للأبحاث الصيدلانية بتنظيم دورتين متخصصتين في التطوير و التحليل الصيدلاني النظري و العملي لمجموعتين من كوادر قطاع الصناعة الدوائية و ذلك بالتنسيق مع وزارة الصناعة و المعادن في جمهورية ...

 فارما جو – د. مالك السعدي في ظل تحقيق اهداف الاتحاد العربي لمنتجي الادوية والمستلزمات الطبية وسعيا منه في النهوض بالصناعة الدوائية العربية , ينوي الاتحادعقد منتدى حول الشؤون التنظيمية  للدواء العربي والمشاكل التي ...

      Results published ahead of presentation at the American Thoracic Society conference showed that Novartis' experimental chronic obstructive pulmonary disease drug NVA237 helped patients and was at least as good as Boehringer Ingelheim and Pfizer's Spiriva, Bloomberg reported Wednesday.     In the late-stage GLOW2 trial, patients taking NVA237 were able to expel an average of 97 ...

Citing sources with knowledge of the matter, the Wall Street Journal reported Tuesday that Pfizer is close to selling its infant-nutrition business to Nestlé in a transaction valued at more than $9 billion. The people noted that an announcement of a deal could come as early as next week. To win approval from antitrust regulators, the sources suggested that Nestlé would likely have to ...

Pfizer's Wyeth unit is seeking $960 million in damages from Sun Pharmaceutical for alleged patent infringement following the launch of a generic version of Protonix (pantoprazole) in the US, the Indian company said. Sun Pharmaceutical indicated that it "believes that it has sound reasons to disagree with these overstated claims of Wyeth, and also continues to believe that the patent is ...

فارما جو – عمان قدمت شركة الرام للصناعات الدوائية التي تاسست في الأردن في العام 1993م ، وضمن سياستها بالتواصل مع المجتمع المحلي عدد من المنح الدراسية الجامعية لعدد من الطلاب المتميزين الذين لا تساعدهم ظروفهم المادية ...

Novartis announced Friday that it will cut around 1960 jobs in the US as part of a restructuring of its general medicines business in preparation for the loss of patent exclusivity on Diovan (valsartan) in the US in September. The company said it will also record charges totalling more than $1.2 billion due in part to a "reassessment of the future sales potential" of Rasilez (aliskiren) ...

Final draft guidance published Friday by the National Institute for Health and Clinical Excellence confirmed an earlier recommendation supporting NHS reimbursement of Eli Lilly, Amylin and Alkermes' Bydureon (extended-release exenatide) for certain people with type 2 diabetes. The agency said the once-weekly GLP-1 receptor agonist could be given in combination with certain other drugs in ...

AstraZeneca announced two licensing deals Wednesday to bolster its drug pipeline, a day after reporting that it will record a charge of $381.5 million related to setbacks for other experimental compounds. Under the first agreement, AstraZeneca obtained an option from Astellas' Prosidion unit to acquire the two G protein-coupled receptor GPR119 agonists PSN821 and PSN842, which are being ...

The National Institute for Health and Clinical Excellence issued final guidance Wednesday, recommending against NHS reimbursement of Novartis' Lucentis (ranibizumab) for the treatment of diabetic macular oedema (DMO). The drugmaker said it would "continue to work with NICE and the UK department of health toward a solution that will allow patients access" to the treatment. The decision, ...